Fufang-Biejia-Ruangan tablet targeting both cancer-associated fibroblasts and tumor cells by HIPPO-PI3K/AKT cascades in intrahepatic cholangiocarcinoma treatment
Our research demonstrates BJRG's anti-ICC efficacy via diverse pathways, including the suppression of tumor cell proliferation, regulation of CAFs activity, and promotion of immune cell infiltration. These findings underscore BJRG as a promising therapeutic candidate for ICC, offering novel mechanistic insights and highlighting its potential for clinical translation.
Authors
- Zhiyun Yang (ORCID: https://orcid.org/0000-0002-1522-0749)
- Miao Cui (ORCID: https://orcid.org/0000-0002-3402-8664)
- Xinhua Song (ORCID: https://orcid.org/0000-0002-8232-6869)
- Xiang Li (ORCID: https://orcid.org/0000-0001-6951-6900)
- Shuwen Zheng (ORCID: https://orcid.org/0009-0006-7874-5477)
- Jiabo Wang (ORCID: https://orcid.org/0000-0002-1386-0435)
- Di Yin (ORCID: https://orcid.org/0000-0002-3272-9643)
- Yang Xu (ORCID: https://orcid.org/0000-0001-5574-921X)
- Tao Pan (ORCID: https://orcid.org/0000-0003-0278-4278)
- Zimeng Shang
- Yanyu Xu
Institutions
- Fujian University of Traditional Chinese Medicine (CN)
- Beijing YouAn Hospital (CN)
- Beijing Hospital of Traditional Chinese Medicine (CN)
- Beijing Ditan Hospital (CN)
Publication Details
- Journal
- Phytomedicine
- Published
- 2025-03-31
- DOI
- https://doi.org/10.1016/j.phymed.2025.156690
- Citations
- 2
- Primary Topic
- Cancer Mechanisms and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- National Key Research and Development Program of China